110 related articles for article (PubMed ID: 34289901)
1. DNA methylation characteristics associated with chemotherapy resistance in epithelial ovarian cancer.
Duan C; Yan Z; Wu C; Zhou X; Bao W
Heliyon; 2024 Mar; 10(5):e27212. PubMed ID: 38468944
[TBL] [Abstract][Full Text] [Related]
2. Comparing the Secretomes of Chemorefractory and Chemoresistant Ovarian Cancer Cell Populations.
Lee AH; Mejia Peña C; Dawson MR
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326569
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of BRD4 isoforms long (BRD4-L) and short (BRD4-S) promotes chemotherapy resistance in high-grade serous ovarian carcinoma.
Drumond-Bock AL; Wang L; Wang L; Cybula M; Rostworowska M; Kinter M; Bieniasz M
Genes Cancer; 2023; 14():56-76. PubMed ID: 37705995
[TBL] [Abstract][Full Text] [Related]
4. Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.
Patch AM; Christie EL; Etemadmoghadam D; Garsed DW; George J; Fereday S; Nones K; Cowin P; Alsop K; Bailey PJ; Kassahn KS; Newell F; Quinn MC; Kazakoff S; Quek K; Wilhelm-Benartzi C; Curry E; Leong HS; ; Hamilton A; Mileshkin L; Au-Yeung G; Kennedy C; Hung J; Chiew YE; Harnett P; Friedlander M; Quinn M; Pyman J; Cordner S; O'Brien P; Leditschke J; Young G; Strachan K; Waring P; Azar W; Mitchell C; Traficante N; Hendley J; Thorne H; Shackleton M; Miller DK; Arnau GM; Tothill RW; Holloway TP; Semple T; Harliwong I; Nourse C; Nourbakhsh E; Manning S; Idrisoglu S; Bruxner TJ; Christ AN; Poudel B; Holmes O; Anderson M; Leonard C; Lonie A; Hall N; Wood S; Taylor DF; Xu Q; Fink JL; Waddell N; Drapkin R; Stronach E; Gabra H; Brown R; Jewell A; Nagaraj SH; Markham E; Wilson PJ; Ellul J; McNally O; Doyle MA; Vedururu R; Stewart C; Lengyel E; Pearson JV; Waddell N; deFazio A; Grimmond SM; Bowtell DD
Nature; 2015 Nov; 527(7578):398. PubMed ID: 26503049
[No Abstract] [Full Text] [Related]
5. Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers.
Chan DW; Lam WY; Chen F; Yung MMH; Chan YS; Chan WS; He F; Liu SS; Chan KKL; Li B; Ngan HYS
Clin Epigenetics; 2021 Jul; 13(1):142. PubMed ID: 34294135
[TBL] [Abstract][Full Text] [Related]
6. Cancer-associated fibroblasts contribute to cancer metastasis and apoptosis resistance in human ovarian cancer via paracrine SDF-1α.
Dai JM; Sun K; Li C; Cheng M; Guan JH; Yang LN; Zhang LW
Clin Transl Oncol; 2023 Jun; 25(6):1606-1616. PubMed ID: 36593384
[TBL] [Abstract][Full Text] [Related]
7. Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options.
Nunes M; Bartosch C; Abreu MH; Richardson A; Almeida R; Ricardo S
Cells; 2024 May; 13(9):. PubMed ID: 38727322
[TBL] [Abstract][Full Text] [Related]
8. The role of DNA methylation in ovarian cancer chemoresistance: A narrative review.
Song K; Artibani M
Health Sci Rep; 2023 May; 6(5):e1235. PubMed ID: 37123549
[TBL] [Abstract][Full Text] [Related]
9. Ovarian Cancer-Insights into Platinum Resistance and Overcoming It.
Havasi A; Cainap SS; Havasi AT; Cainap C
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984544
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic and Genetic Population Structure is Coupled in a Marine Invertebrate.
Silliman K; Spencer LH; White SJ; Roberts SB
Genome Biol Evol; 2023 Feb; 15(2):. PubMed ID: 36740242
[TBL] [Abstract][Full Text] [Related]
11. PCDH17 gene promoter methylation status in a cohort of Egyptian women with epithelial ovarian cancer.
Elsharkawi SM; Elkaffash D; Moez P; El-Etreby N; Sheta E; Taleb RSZ
BMC Cancer; 2023 Jan; 23(1):89. PubMed ID: 36698136
[TBL] [Abstract][Full Text] [Related]
12. The Methylation Game: Epigenetic and Epitranscriptomic Dynamics of 5-Methylcytosine.
Alagia A; Gullerova M
Front Cell Dev Biol; 2022; 10():915685. PubMed ID: 35721489
[TBL] [Abstract][Full Text] [Related]
13. Computational Analysis of High-Dimensional DNA Methylation Data for Cancer Prognosis.
Hu R; Zhou XJ; Li W
J Comput Biol; 2022 Aug; 29(8):769-781. PubMed ID: 35671506
[TBL] [Abstract][Full Text] [Related]
14. Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer.
Guo Y; Yang N; Li G; Yin X; Dong L
J Immunol Res; 2022; 2022():4379216. PubMed ID: 35647204
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Analysis of DNA Methylation and Transcriptome to Identify PD-1-Negative Prognostic Methylated Signature in Endometrial Carcinoma.
Cao L; Ma X; Rong P; Zhang J; Yang M; Wang W
Dis Markers; 2022; 2022():3085289. PubMed ID: 35634444
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer.
Matthews BG; Bowden NA; Wong-Brown MW
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885103
[TBL] [Abstract][Full Text] [Related]
17. Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer.
Feng LY; Yan BB; Huang YZ; Li L
Clin Epigenetics; 2021 Jul; 13(1):141. PubMed ID: 34289901
[TBL] [Abstract][Full Text] [Related]
18. LAMA3 DNA methylation and transcriptome changes associated with chemotherapy resistance in ovarian cancer.
Feng LY; Huang YZ; Zhang W; Li L
J Ovarian Res; 2021 May; 14(1):67. PubMed ID: 33992120
[TBL] [Abstract][Full Text] [Related]
19. Low expression of NCALD is associated with chemotherapy resistance and poor prognosis in epithelial ovarian cancer.
Feng LY; Li L
J Ovarian Res; 2020 Mar; 13(1):35. PubMed ID: 32228639
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
